BioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem® Program

--Patent provides protection in key international markets for BioRestorative’s ThermoStem^® program targeting obesity and metabolic disorders, including type 2 diabetes--

MELVILLE, N.Y., Feb. 08, 2023 (GLOBE NEWSWIRE) -- (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:), a clinical stage company focused on stem cell-based therapies, today announced that the European Patent Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem^® program. The notice of allowance was issued on February 6, 2023.

Claims granted under the new patent cover implantable three-dimensional scaffolds and brown adipocytes that have been derived from human brown adipose-derived stem cells. The therapeutic combination of scaffolds as a delivery system and brown adipose-derived stem cells provides the ability to deliver metabolically active cells. Therapeutic benefits of using brown adipose have been demonstrated in various models and may provide a valuable therapeutic tool for treating a range of metabolic disorders in multi-billion dollar markets. Certain companies that use encapsulation technology coupled with cells have shown promising clinical results treating type 1 diabetes in their Phase 1/2 clinical trials.

“Our patent family for our ThermoStem^® program continues to grow as we receive additional patent grants in key markets,” said Lance Alstodt, the Company’s CEO. “We are committed to the development of ThermoStem^® as a potential treatment for obesity and metabolic disorders, such as type 2 diabetes. This patent, which covers a manufacturing process for ThermoStem^® developed by BioRestorative’s scientists, enhances our ability to do so in European jurisdictions.”

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. () develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

• Disc/Spine Program (brtxDISC^™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease.

• Metabolic Program (ThermoStem^®): We are developing a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. 

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:

Email: